# Gero Pte.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gero-pte

- Industry: Biotechnology
- Headquarters: Singapore, Singapore
- Website: www.gero.ai
- Total disclosed funding: $8.8M
- Latest round: Series A (Oct 18, 2023)
- Investors on record: 2

## About

Based in Singapore, Gero Private Limited operates in the healthcare technology sector, utilizing artificial intelligence to tackle complex diseases and the aging process, aiming to improve patient outcomes through innovative solutions. Gero Private Limited specializes in healthcare technology solutions, focusing on AI-driven approaches to understand chronic diseases and aging. Founded in 2015, the company is headquartered in Singapore. The founding team includes Ignacio Brea, Mariano Russo, Maxim Kholin, Peter Fedichev, and Sergei Filonov, with Ignacio Brea and Peter Fedichev serving as co-CEOs. In June 2026, Gero Pte. Ltd. raised USD 17 million in venture funding from Melnichek Investments. GERO.AI specializes in advanced solutions targeting complex diseases and aging processes. The company employs artificial intelligence and machine learning to analyze genomic and clinical data, aiming to offer insights that contribute to understanding and potentially curing chronic diseases. Its primary customers include researchers, healthcare providers, and biomedical institutions, particularly in Singapore and other biotechnology-centric regions. In 2022, GERO.AI reported revenues of USD 518,311 with an EBITDA of USD -1,463,951, which reflects the company's investment focus and growth strategy in the healthcare technology space. The company will use the June 2026 funding to advance preclinical development of its pipeline and expand partnerships with pharmaceutical firms.

## Funding rounds

- Series A, Oct 18, 2023, $6M — Melnichek Investments, VitaDAO
- Series B, Apr 19, 2023, $2.8M — Melnichek Investments

## Investors

- Melnichek Investments (https://capitalatlas.ai/funds/melnichek-investments) — Series B, Series A
- VitaDAO — Series A